Hyperfine, Inc. (HYPR) vs Verrica Pharmaceuticals Inc. (VRCA)
A side-by-side comparison of Hyperfine, Inc. and Verrica Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
HYPR
Hyperfine, Inc.
$0.88HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT
VRCA
Verrica Pharmaceuticals Inc.
$4.28HealthcareDelayed quote: Oct 6, 2026, 3:37 PM EDT
Total return — HYPR vs VRCA
growth of $100 · dividends reinvested · last 6yHYPR -91.2% (-33.3%/yr)VRCA -96.3% (-42.2%/yr)HYPR compounded faster over this window
HYPR VRCA
HYPR vs VRCA: by the numbers
- •HYPR is the larger company ($74M vs $74M market cap).
- •Both run net losses; VRCA's is the smaller (-102.84% vs -210.75% net margin).
- •HYPR grew revenue faster over the past five years (77.73% vs 20.37% CAGR).
Metrics side by side
Valuation
| Metric | HYPR | VRCA |
|---|---|---|
| P/S ratio | 4.46 | 2.43 |
| P/B ratio | 2.01 | 17.08 |
Profitability
| Metric | HYPR | VRCA |
|---|---|---|
| Gross margin | 51.41% | 85.89% |
| Operating margin | -273.43% | -33.56% |
| Net margin | -210.75% | -102.84% |
| ROE | -94.81% | -724.01% |
| ROIC | -62.98% | -207.23% |
Growth (annualized)
| Metric | HYPR | VRCA |
|---|---|---|
| Revenue CAGR (5Y) | 77.73% | 20.37% |
| Total return CAGR (5Y) | -38.34% | -48.68% |
Frequently asked
- Which has grown faster, HYPR or VRCA?
- Over the past five years, HYPR grew revenue faster — HYPR at a 77.73% CAGR versus VRCA at 20.37%.
- How have HYPR and VRCA total returns compared?
- Over the past 5 years, HYPR delivered -38.34% and VRCA delivered -48.68% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Hyperfine ROEVerrica Pharmaceuticals ROEHyperfine operating marginVerrica Pharmaceuticals operating marginHyperfine revenue growthVerrica Pharmaceuticals revenue growthHyperfine free cash flowVerrica Pharmaceuticals free cash flow
Hyperfine & Verrica Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.